Gilead posts ARTISTRY-2 results; registers GS-1179 herpes trial and ARTISTRY-3 HIV study
Gilead reported Phase 3 results for bictegravir/lenacapavir versus Biktarvy and listed two new registry records this week.
Gilead Sciences posted results from a completed Phase 3 HIV trial and registered two new studies this week.
- Gilead posted results for "ARTISTRY-2" (NCT06333808), a Phase 3 trial comparing bictegravir/lenacapavir fixed-dose combination against Biktarvy in virologically suppressed people with HIV-1. The study enrolled 577 participants.1 Its primary outcome measured the percentage of participants with HIV-1 RNA of 50 copies/mL or more at Week 48, using the FDA snapshot algorithm, in a window between Days 295 and 378.1 Results were first posted on 2026-11-05.
- Gilead registered a Phase 2b trial (NCT07912996) testing its investigational drug GS-1179 against valacyclovir in HSV-2 seropositive people with recurrent genital herpes. The primary objective is to evaluate the safety and tolerability of GS-1179 versus valacyclovir and to assess GS-1179's antiviral effect.2 Enrollment is estimated at 300 participants (estimated).2 The trial is not yet recruiting.
- Gilead registered "ARTISTRY-3" (NCT07908446), a Phase 4, open-label, non-inferiority trial comparing bictegravir/lenacapavir fixed-dose combination with participants' existing stable baseline regimens in virologically suppressed people with HIV. Enrollment is estimated at 400 participants.3 The trial is not yet recruiting.
- A Phase II trial of sacituzumab govitecan in recurrent and/or metastatic salivary gland cancers remains active not recruiting. The lead sponsor is M.D. Anderson Cancer Center, with Gilead Sciences as a collaborator.4
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.